
CorMedix Inc.: updates and filings
Price
$5.08
November 19, 2026Market cap $402M
What Ploutos Investor adds for CorMedix
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2012
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 12, 2026next Feb 12, 2027
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
November 2026
- 12ThuReportQuarterly report · for the period to Sep 30, 2026Document
- 12ThuResultsResults of operationsDocument
- 9MonDealMaterial agreement entered, new material financial obligation, unregistered sale of shares, Regulation FD disclosureDocument
- 2MonResultsResults of operations, Regulation FD disclosureDocument
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026SOLICITING MATERIAL PURSUANT TO 240.14A-12FormDFAN14A
- Nov 16, 2026Additional annual meeting materialFormDEFA14A
- Nov 16, 2026Regulation FD disclosureForm8-K
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 12, 2026Results of operationsForm8-K
- Nov 10, 2026Additional annual meeting materialFormDEFA14A
- Nov 10, 2026Regulation FD disclosureForm8-K
- Nov 9, 2026Additional annual meeting materialFormDEFA14A
- Nov 9, 2026Material agreement entered, new material financial obligation, unregistered sale of shares, Regulation FD disclosureForm8-K
- Nov 2, 2026Results of operations, Regulation FD disclosureForm8-K
- Oct 19, 2026Regulation FD disclosureForm8-K
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operationsForm8-K
- Aug 7, 2026Other material eventsForm8-K
- Jul 2, 2026Other material eventsForm8-K
- Jul 1, 2026Change of auditorForm8-K
- Jun 25, 2026FilingFormS-8 POS
- Jun 24, 2026Shareholder voteForm8-K
- Jun 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 12, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 8, 2026Regulation FD disclosureForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Results of operationsForm8-K
- Apr 29, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | DFAN14A | SOLICITING MATERIAL PURSUANT TO 240.14A-12 | Document |
| Nov 16, 2026 | DEFA14A | Additional annual meeting material | Document |
| Nov 16, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 12, 2026 | 8-K | Results of operations | Document |
| Nov 10, 2026 | DEFA14A | Additional annual meeting material | Document |
| Nov 10, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 9, 2026 | DEFA14A | Additional annual meeting material | Document |
| Nov 9, 2026 | 8-K | Material agreement entered, new material financial obligation, unregistered sale of shares, Regulation FD disclosure | Document |
| Nov 2, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Oct 19, 2026 | 8-K | Regulation FD disclosure | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations | Document |
| Aug 7, 2026 | 8-K | Other material events | Document |
| Jul 2, 2026 | 8-K | Other material events | Document |
| Jul 1, 2026 | 8-K | Change of auditor | Document |
| Jun 25, 2026 | S-8 POS | Filing | Document |
| Jun 24, 2026 | 8-K | Shareholder vote | Document |
| Jun 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 12, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 8, 2026 | 8-K | Regulation FD disclosure | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 14, 2007.
The full analysis
What do CorMedix's filings show?
The filings are where every one of CorMedix's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.